Answers are grounded in this paper and cite their sources.
Meta-analysis shows ocrelizumab reduces relapse rates in multiple sclerosis, suggesting well-managed safety but uncertain long-term effects.
This study confirms OCR's significant efficacy in reducing relapse rates and its manageable safety profile in MS. However, its benefits on composite endpoints like NEDA and on halting disability progression remain uncertain and variable, highlighting a need for long-term studies to better define its role in mitigating disease progression.
No takes yet. Share an insight, caveat, or question.
Nawaz et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: